Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Neoplasms 11Breast Neoplasms 10Head and Neck Neoplasms 5Lung Neoplasms 3Carcinoma, Squamous Cell 3Adenocarcinoma 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thoracic Neoplasms 1Squamous Non-small Cell Lung Cancer 1Squamous Cell Cancers of the Head and Neck 1Rhabdomyosarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Neuroectodermal Tumors 1Neoplasms by Site 1Lung Diseases 1

Interventions

Gemcitabine 7Cisplatin 5Ramucirumab 3Platinum 3Paclitaxel 3Docetaxel 31,2-diaminocyclohexaneplatinum II citrate 3pembrolizumab 2Carboplatin 2rucaparib 1pegfilgrastim 1pazopanib 1eribulin 1enzalutamide 1enfortumab vedotin 1dehydroftorafur 1cabozantinib 1avelumab 1atezolizumab 1aflibercept 1Taxes 1Surgical Procedures, Operative 1Sunitinib 1Standard of Care 1Specimen Handling 1Sorafenib 1Radiotherapy 1Radiation 1N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide 1Mitozytrex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urethral Neoplasms × Afatinib × Clear all
NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

University of Chicago

Phase 2 Terminated
32 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡